In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances

Progress in Biophysics and Molecular Biology

Volumn 119, Issue 1, 2015, Pages 20-32

  Kuenemann, Mélaine A ^a,b   Sperandio, Olivier ^a,b,c   Labbé, Céline M ^a,b,c   Lagorce, David ^a,b   Miteva, Maria A ^a,b   Villoutreix, Bruno O ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

Bioinformatics; Chemoinformatics; Compound collection; Focused library; Protein protein interaction inhibitors; Virtual screening

Indexed keywords

LIGAND; MOLECULAR LIBRARY;

ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULAR WEIGHT; PHARMACOKINETICS; PHARMACOLOGY; PROTEIN PROTEIN INTERACTION;

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR WEIGHT; PROTEIN INTERACTION MAPS; SMALL MOLECULE LIBRARIES;

EID: 84940891441     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.02.006     Document Type: Review

References (225)

1. Alex A., Millan D.S., Perez M., Wakenhut F., Whitlock G.A. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med. Chem. Commun. 2011, 2:669-674.
2. Alvarez-Garcia D., Barril X. Molecular simulations with solvent competition quantify water displaceability and provide accurate interaction maps of protein binding sites. J. Med. Chem. 2014, 57:8530-8539.
3. Andreani J., Guerois R. Evolution of protein interactions: from interactomes to interfaces. Arch. Biochem. Biophys. 2014, 554:65-75.
4. Arkin M.R., Tang Y., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 2014, 21:1102-1114.
5. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 2004, 3:301-317.
6. Autin L., Steen M., Dahlback B., Villoutreix B.O. Proposed structural models of the prothrombinase (FXa-FVa) complex. Proteins 2006, 63:440-450.
7. Azzarito V., Long K., Murphy N.S., Wilson A.J. Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules. Nat. Chem. 2013, 5:161-173.
8. Baaden M., Marrink S.J. Coarse-grain modelling of protein-protein interactions. Curr. Opin. Struct. Biol. 2013, 23:878-886.
9. Baell J., Walters M.A. Chemistry: chemical con artists foil drug discovery. Nature 2014, 513:481-483.
10. Baell J.B., Holloway G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 53:2719-2740.
11. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 2002, 1:882-894.
12. Basse M.J., Betzi S., Bourgeas R., Bouzidi S., Chetrit B., Hamon V., Morelli X., Roche P. 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 2013, 41:D824-D827.
13. Benigni R., Bossa C. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem. Rev. 2011, 111:2507-2536.
14. Bienstock R.J. Computational drug design targeting protein-protein interactions. Curr. Pharm. Des. 2012, 18:1240-1254.
15. Bogan A.A., Thorn K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280:1-9.
16. Bohnert T., Gan L.S. Plasma protein binding: from discovery to development. J. Pharm. Sci. 2013, 102:2953-2994.
17. Bohnuud T., Kozakov D., Vajda S. Evidence of conformational selection driving the formation of ligand binding sites in protein-protein interfaces. PLoS Comput. Biol. 2014, 10:e1003872.
18. Bologa C.G., Olah M.M., Oprea T.I. Chemical database preparation for compound acquisition or virtual screening. Methods Mol. Biol. 2006, 316:375-388.
19. Brown S.P., Hajduk P.J. Effects of conformational dynamics on predicted protein druggability. ChemMedChem 2006, 1:70-72.
20. Bruncko M., Tahir S.K., Song X., Chen J., Ding H., Huth J.R., Jin S., Judge R.A., Madar D.J., Park C.H., Park C.M., Petros A.M., Tse C., Rosenberg S.H., Elmore S.W. N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors. Bioorg. Med. Chem. Lett. 2010, 20:7503-7506.
21. Buchwald P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 2010, 62:724-731.
22. Bullock B.N., Jochim A.L., Arora P.S. Assessing helical protein interfaces for inhibitor design. J. Am. Chem. Soc. 2011, 133:14220-14223.
23. Cavasotto C.N., Phatak S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 2009, 14:676-683.
24. Chen C.Y., Tou W.I. How to design a drug for the disordered proteins?. Drug Discov. Today 2013, 18:910-915.
25. Chen D., Ranganathan A., AP I.J., Siegal G., Carlsson J. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. J. Chem. Inf. Model. 2013, 53:2701-2714.
26. Chen J., Sawyer N., Regan L. Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci. 2013, 22:510-515.
27. Chen K., Mizianty M.J., Gao J., Kurgan L. A critical comparative assessment of predictions of protein-binding sites for biologically relevant organic compounds. Structure 2011, 19:613-621.
28. Cherkasov A., Muratov E.N., Fourches D., Varnek A., Baskin, Cronin M., Dearden J., Gramatica P., Martin Y.C., Todeschini R., Consonni V., Kuz'min V.E., Cramer R., Benigni R., Yang C., Rathman J., Terfloth L., Gasteiger J., Richard A., Tropsha A. QSAR modeling: where have you been? Where are you going to?. J. Med. Chem. 2014, 26:4977-5010.
29. Chovancova E., Pavelka A., Benes P., Strnad O., Brezovsky J., Kozlikova B., Gora A., Sustr V., Klvana M., Medek P., Biedermannova L., Sochor J., Damborsky J. CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures. PLoS Comput. Biol. 2012, 8:e1002708.
30. Cierpicki T., Grembecka J. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?. Immunol. Rev. 2015, 263:279-301.
31. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
32. Clark D.E. What has virtual screening ever done for drug discovery?. Expert Opin. Drug Discov. 2008, 3:841-851.
33. Craig I.R., Pfleger C., Gohlke H., Essex J.W., Spiegel K. Pocket-space maps to identify novel binding-site conformations in proteins. J. Chem. Inf. Model. 2011, 51:2666-2679.
34. Craik D.J., Fairlie D.P., Liras S., Price D. The future of peptide-based drugs. Chem. Biol. Drug Des. 2013, 81:136-147.
35. Cross S., Cruciani G. Molecular fields in drug discovery: getting old or reaching maturity?. Drug Discov. Today 2010, 15:23-32.
36. Cruciani G., Pastor M., Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11(Suppl. 2):S29-S39.
37. Cukuroglu E., Engin H.B., Gursoy A., Keskin O. Hot spots in protein-protein interfaces: towards drug discovery. Prog. Biophys. Mol. Biol. 2014, 116:165-173.
38. Cummings C.G., Hamilton A.D. Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr. Opin. Chem. Biol. 2010, 14:341-346.
39. Dahlin J.L., Walters M.A. The essential roles of chemistry in high-throughput screening triage. Future Med. Chem. 2014, 6:1265-1290.
40. Davies J.W., Glick M., Jenkins J.L. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr. Opin. Chem. Biol. 2006, 10:343-351.
41. Dessailly B.H., Dawson N.L., Mizuguchi K., Orengo C.A. Functional site plasticity in domain superfamilies. Biochim. Biophys. Acta 2013, 1834:874-889.
42. Devine S.M., Mulcair M.D., Debono C.O., Leung E.W., Nissink J.W., Lim S.S., Chandrashekaran I.R., Vazirani M., Mohanty B., Simpson J.S., Baell J.B., Scammells P.J., Norton R.S., Scanlon M.J. Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. J. Med. Chem. 2015, 58:1205-1214.
43. Dias D.M., Van Molle I., Baud M.G., Galdeano C., Geraldes C.F., Ciulli A. Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?. ACS Med. Chem. Lett. 2014, 5:23-28.
44. Doak B.C., Over B., Giordanetto F., Kihlberg J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 2014, 21:1115-1142.
45. Dragiev P., Nadon R., Makarenkov V. Systematic error detection in experimental high-throughput screening. BMC Bioinform. 2011, 12:25.
46. Edfeldt F.N., Folmer R.H., Breeze A.L. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today 2011, 16:284-287.
47. Ekins S., Mestres J., Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol. 2007, 152:21-37.
48. Ekins S., Mestres J., Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol. 2007, 152:9-20.
49. Ettorre A., D'Andrea P., Mauro S., Porcelloni M., Rossi C., Altamura M., Catalioto R.M., Giuliani S., Maggi C.A., Fattori D. hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg. Med. Chem. Lett. 2011, 21:1807-1809.
50. Eyrisch S., Helms V. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem. 2007, 50:3457-3464.
51. Falchi F., Caporuscio F., Recanatini M. Structure-based design of small-molecule protein-protein interaction modulators: the story so far. Future Med. Chem. 2014, 6:343-357.
52. Faller B., Ottaviani G., Ertl P., Berellini G., Collis A. Evolution of the physicochemical properties of marketed drugs: can history foretell the future?. Drug Discov. Today 2011, 16:976-984.
53. Fan H., Irwin J.J., Webb B.M., Klebe G., Shoichet B.K., Sali A. Molecular docking screens using comparative models of proteins. J. Chem. Inf. Model. 2009, 49:2512-2527.
54. Fauman E.B., Rai B.K., Huang E.S. Structure-based druggability assessment - identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol. 2011, 15:463-468.
55. Fayne D. De-peptidising protein-protein interactions - big jobs for small molecules. Drug Discov. Today Technol. 2013, 10:e467-e474.
56. Fernandez-Recio J. Prediction of protein binding sites and hot spots. WIREs Comput. Mol. Sci. 2011, 1:680-698.
57. Ferreira R.S., Simeonov A., Jadhav A., Eidam O., Mott B.T., Keiser M.J., McKerrow J.H., Maloney D.J., Irwin J.J., Shoichet B.K. Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J. Med. Chem. 2010, 53:4891-4905.
58. Fry D., Huang K.S., Di Lello P., Mohr P., Muller K., So S.S., Harada T., Stahl M., Vu B., Mauser H. Design of libraries targeting protein-protein interfaces. ChemMedChem 2013, 8:726-732.
59. Fuller J.C., Burgoyne N.J., Jackson R.M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 2009, 14:155-161.
60. Garzon J.I., Kovacs J., Abagyan R., Chacon P. DFprot: a webtool for predicting local chain deformability. Bioinformatics 2007, 23:901-902.
61. Gautier B., Miteva M.A., Goncalves V., Huguenot F., Coric P., Bouaziz S., Seijo B., Gaucher J.F., Broutin I., Garbay C., Lesnard A., Rault S., Inguimbert N., Villoutreix B.O., Vidal M. Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening. Chem. Biol. 2011, 18:1631-1639.
62. Giordanetto F., Schafer A., Ottmann C. Stabilization of protein-protein interactions by small molecules. Drug Discov. Today 2014, 19:1812-1821.
63. Gleeson M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51:817-834.
64. Gowthaman R., Deeds E.J., Karanicolas J. Structural properties of non-traditional drug targets present new challenges for virtual screening. J. Chem. Inf. Model. 2013, 53:2073-2081.
65. Grosdidier S., Fernandez-Recio J. Protein-protein docking and hot-spot prediction for drug discovery. Curr. Pharm. Des. 2012, 18:4607-4618.
66. Grove L.E., Hall D.R., Beglov D., Vajda S., Kozakov D. FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots. Bioinformatics 2013, 29:1218-1219.
67. Gul S., Hadian K. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays. Expert Opin. Drug Discov. 2014, 9:1393-1404.
68. Hajduk P.J., Huth J.R., Fesik S.W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 48:2518-2525.
69. Hajduk P.J., Huth J.R., Tse C. Predicting protein druggability. Drug Discov. Today 2005, 10:1675-1682.
70. Hamon V., Bourgeas R., Ducrot P., Theret I., Xuereb L., Basse M.J., Brunel J.M., Combes S., Morelli X., Roche P. 2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine. J. R. Soc. Interface 2013, 11:20130860.
71. Hann M.M., Keseru G.M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 2012, 11:355-365.
72. Harvey A.L., Edrada-Ebel R., Quinn R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 2015, 14:111-129.
73. Heikamp K., Bajorath J. The future of virtual compound screening. Chem. Biol. Drug Des. 2013, 81:33-40.
74. Hernandez M., Ghersi D., Sanchez R. SITEHOUND-web: a server for ligand binding site identification in protein structures. Nucleic Acids Res. 2009, 37:W413-W416.
75. Higueruelo A.P., Jubb H., Blundell T.L. Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 2013, 13:791-796.
76. Higueruelo A.P., Jubb H., Blundell T.L. TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions. Database (Oxford) 2013, 2013, bat039.
77. Higueruelo A.P., Schreyer A., Bickerton G.R., Pitt W.R., Groom C.R., Blundell T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 2009, 74:457-467.
78. Hopkins A.L., Witty M.J., Nwaka S. Mission possible. Nature 2007, 449:166-169.
79. Huang N., Jacobson M.P. Binding-site assessment by virtual fragment screening. PLoS One 2010, 5:e10109.
80. Hughes J.D., Blagg J., Price D.A., Bailey S., Decrescenzo G.A., Devraj R.V., Ellsworth E., Fobian Y.M., Gibbs M.E., Gilles R.W., Greene N., Huang E., Krieger-Burke T., Loesel J., Wager T., Whiteley L., Zhang Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18:4872-4875.
81. Illendula A., Pulikkan J.A., Zong H., Grembecka J., Xue L., Sen S., Zhou Y., Boulton A., Kuntimaddi A., Gao Y., Rajewski R.A., Guzman M.L., Castilla L.H., Bushweller J.H. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFbeta-SMMHC delays leukemia in mice. Science 2015, 347:779-784.
82. Jain A.N. Virtual screening in lead discovery and optimization. Curr. Opin. Drug Discov. Dev. 2004, 7:396-403.
83. Janin J., Bahadur R.P., Chakrabarti P. Protein-protein interaction and quaternary structure. Q. Rev. Biophys. 2008, 41:133-180.
84. Janin J., Chothia C. The structure of protein-protein recognition sites. J. Biol. Chem. 1990, 265:16027-16030.
85. Jin L., Wang W., Fang G. Targeting protein-protein interaction by small molecules. Annu. Rev. Pharmacol. Toxicol. 2014, 54:435-456.
86. Johnson D.K., Karanicolas J. Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comput. Biol. 2013, 9:e1002951.
87. Johnsson N. Analyzing protein-protein interactions in the post-interactomic era. Are we ready for the endgame?. Biochem. Biophys. Res. Commun. 2014, 445:739-745.
88. Jones S., Thornton J.M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13-20.
89. Jubb H., Blundell T.L., Ascher D.B. Flexibility and small pockets at protein-protein interfaces: new insights into druggability. Prog. Biophys. Mol. Biol. 2015, 119:2-9.
90. Jubb H., Higueruelo A.P., Winter A., Blundell T.L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 2012, 33:241-248.
91. Kalidas Y., Chandra N. PocketDepth: a new depth based algorithm for identification of ligand binding sites in proteins. J. Struct. Biol. 2008, 161:31-42.
92. Kapetanovic I.M. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem. Biol. Interact. 2008, 171:165-176.
93. Kar S., Roy K. How far can virtual screening take us in drug discovery?. Expert Opin. Drug Discov. 2013, 8:245-261.
94. Kaspar A.A., Reichert J.M. Future directions for peptide therapeutics development. Drug Discov. Today 2013, 18:807-817.
95. Kastritis P.L., Bonvin A.M. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J. R. Soc. Interface 2013, 10:20120835.
96. Kastritis P.L., Rodrigues J.P., Bonvin A.M. HADDOCK(2P2I): a biophysical model for predicting the binding affinity of protein-protein interaction inhibitors. J. Chem. Inf. Model. 2014, 54:826-836.
97. Keskin O., Gursoy A., Ma B., Nussinov R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact?. Chem. Rev. 2008, 108:1225-1244.
98. Khan W., Duffy F., Pollastri G., Shields D.C., Mooney C. Predicting binding within disordered protein regions to structurally characterised peptide-binding domains. PLoS One 2013, 8:e72838.
99. Kinch M.S. An overview of FDA-approved biologics medicines. Drug Discov. Today 2014, S1359-S6446.
100. Kinch M.S. The rise (and decline?) of biotechnology. Drug Discov. Today 2014, 19:1686-1690.
101. Koes D.R., Camacho C.J. Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics 2012, 28:784-791.
102. Kozakov D., Hall D.R., Chuang G.Y., Cencic R., Brenke R., Grove L.E., Beglov D., Pelletier J., Whitty A., Vajda S. Structural conservation of druggable hot spots in protein-protein interfaces. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13528-13533.
103. Kruger D.M., Jessen G., Gohlke H. How good are state-of-the-art docking tools in predicting ligand binding modes in protein-protein interfaces?. J. Chem. Inf. Model. 2012, 52:2807-2811.
104. Kuenemann M.A., Bourbon L.M., Labbe C.M., Villoutreix B.O., Sperandio O. Which 3D characteristics make an efficient inhibitor of protein-protein interactions?. J. Chem. Inf. Model. 2014, 54:3067-3079.
105. Kufareva I., Chen Y.C., Ilatovskiy A.V., Abagyan R. Compound activity prediction using models of binding pockets or ligand properties in 3D. Curr. Top. Med. Chem. 2012, 12:1869-1882.
106. Kufareva I., Ilatovskiy A.V., Abagyan R. Pocketome: an encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Res. 2012, 40:D535-D540.
107. Labbe C.M., Laconde G., Kuenemann M.A., Villoutreix B.O., Sperandio O. iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov. Today 2013, 18:958-968.
108. Lage K. Protein-protein interactions and genetic diseases: the interactome. Biochim. Biophys. Acta 2014, 1842:1971-1980.
109. Lagorce D., Maupetit J., Baell J., Sperandio O., Tuffery P., Miteva M.A., Galons H., Villoutreix B.O. The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics 2011, 27:2018-2020.
110. Lahti J.L., Tang G.W., Capriotti E., Liu T., Altman R.B. Bioinformatics and variability in drug response: a protein structural perspective. J. R. Soc. Interface 2012, 9:1409-1437.
111. Lao B.B., Drew K., Guarracino D.A., Brewer T.F., Heindel D.W., Bonneau R., Arora P.S. Rational design of topographical helix mimics as potent inhibitors of protein-protein interactions. J. Am. Chem. Soc. 2014, 136:7877-7888.
112. Laurie A.T., Jackson R.M. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005, 21:1908-1916.
113. Le Guilloux V., Schmidtke P., Tuffery P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinform. 2009, 10:168.
114. Leeson P.D., St-Gallay S.A. The influence of the 'organizational factor' on compound quality in drug discovery. Nat. Rev. Drug Discov. 2011, 10:749-765.
115. Leis S., Schneider S., Zacharias M. In silico prediction of binding sites on proteins. Curr. Med. Chem. 2010, 17:1550-1562.
116. Levy E.D. A simple definition of structural regions in proteins and its use in analyzing interface evolution. J. Mol. Biol. 2010, 403:660-670.
117. Li H., Kasam V., Tautermann C.S., Seeliger D., Vaidehi N. Computational method to identify druggable binding sites that target protein-protein interactions. J. Chem. Inf. Model. 2014, 54:1391-1400.
118. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
119. Liu L.K., Finzel B.C. Fragment-based identification of an inducible binding site on cell surface receptor CD44 for the design of protein-carbohydrate interaction inhibitors. J. Med. Chem. 2014, 57:2714-2725.
120. Liu T., Lin Y., Wen X., Jorissen R.N., Gilson M.K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35:D198-D201.
121. London N., Raveh B., Schueler-Furman O. Peptide docking and structure-based characterization of peptide binding: from knowledge to know-how. Curr. Opin. Struct. Biol. 2013, 23:894-902.
122. Lovering F., Bikker J., Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009, 52:6752-6756.
123. Loving K.A., Lin A., Cheng A.C. Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Comput. Biol. 2014, 10:e1003741.
124. Ma B., Nussinov R. Druggable orthosteric and allosteric hot spots to target protein-protein interactions. Curr. Pharm. Des. 2014, 20:1293-1301.
125. Macarron R., Banks M.N., Bojanic D., Burns D.J., Cirovic D.A., Garyantes T., Green D.V., Hertzberg R.P., Janzen W.P., Paslay J.W., Schopfer U., Sittampalam G.S. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 2011, 10:188-195.
126. Makley L.N., Gestwicki J.E. Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem. Biol. Drug Des. 2013, 81:22-32.
127. Mathieu A.L., Sperandio O., Pottiez V., Balzarin S., Herledan A., Elkaim J.O., Fogeron M.L., Piveteau C., Dassonneville S., Deprez B., Villoutreix B.O., Bonnefoy N., Leroux F. Identification of small inhibitory molecules targeting the Bfl-1 anti-apoptotic protein that alleviates resistance to ABT-737. J. Biomol. Screen. 2014, 19:1035-1046.
128. Mazuc E., Villoutreix B.O., Malbec O., Roumier T., Fleury S., Leonetti J.P., Dombrowicz D., Daeron M., Martineau P., Dariavach P. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. J. Allergy Clin. Immunol. 2008, 122(188-94):194.e1-194.e3.
129. McInnes C. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 2007, 11:494-502.
130. Meier C., Cairns-Smith S., Schulze U. Can emerging drug classes improve R&D productivity?. Drug Discov. Today 2013, 18:607-609.
131. Mendgen T., Steuer C., Klein C.D. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J. Med. Chem. 2012, 55:743-753.
132. Metz A., Pfleger C., Kopitz H., Pfeiffer-Marek S., Baringhaus K.H., Gohlke H. Hot spots and transient pockets: predicting the determinants of small-molecule binding to a protein-protein interface. J. Chem. Inf. Model. 2012, 52:120-133.
133. Milroy L.G., Grossmann T.N., Hennig S., Brunsveld L., Ottmann C. Modulators of protein-protein interactions. Chem. Rev. 2014, 114:4695-4748.
134. Mok N.Y., Maxe S., Brenk R. Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries. J. Chem. Inf. Model. 2013, 53:534-544.
135. Moreira I.S., Martins J.M., Ramos R.M., Fernandes P.A., Ramos M.J. Understanding the importance of the aromatic amino-acid residues as hot-spots. Biochim. Biophys. Acta 2013, 1834:404-414.
136. Morelli X., Bourgeas R., Roche P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 2011, 15:475-481.
137. Morley A.D., Pugliese A., Birchall K., Bower J., Brennan P., Brown N., Chapman T., Drysdale M., Gilbert I.H., Hoelder S., Jordan A., Ley S.V., Merritt A., Miller D., Swarbrick M.E., Wyatt P.G. Fragment-based hit identification: thinking in 3D. Drug Discov. Today 2013, 18:1221-1227.
138. Muchmore S.W., Edmunds J.J., Stewart K.D., Hajduk P.J. Cheminformatic tools for medicinal chemists. J. Med. Chem. 2010, 53:4830-4841.
139. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 2012, 11:173-175.
140. Muthas D., Boyer S., Hasselgren C. A critical assessment of modeling safety-related drug attrition. MedChemComm 2013, 4:1058-1065.
141. Nayal M., Honig B. On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. Proteins 2006, 63:892-906.
142. Nero T.L., Morton C.J., Holien J.K., Wielens J., Parker M.W. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer 2014, 14:248-262.
143. Neugebauer A., Hartmann R.W., Klein C.D. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem. 2007, 50:4665-4668.
144. Ngounou Wetie A.G., Sokolowska I., Woods A.G., Roy U., Deinhardt K., Darie C.C. Protein-protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches. Cell. Mol. Life Sci. 2014, 71:205-228.
145. Nooren I.M., Thornton J.M. Diversity of protein-protein interactions. EMBO J. 2003, 22:3486-3492.
146. Nussinov R., Tsai C.J. The design of covalent allosteric drugs. Annu. Rev. Pharmacol. Toxicol. 2015, 55:249-267.
147. Pagliaro L., Felding J., Audouze K., Nielsen S.J., Terry R.B., Krog-Jensen C., Butcher S. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 2004, 8:442-449.
148. Parker C.N., Shamu C.E., Kraybill B., Austin C.P., Bajorath J. Measure, mine, model, and manipulate: the future for HTS and chemoinformatics?. Drug Discov. Today 2006, 11:863-865.
149. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007, 6:29-40.
150. Perot S., Sperandio O., Miteva M.A., Camproux A.C., Villoutreix B.O. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov. Today 2010, 15:656-667.
151. Petrey D., Honig B. Structural bioinformatics of the interactome. Annu. Rev. Biophys. 2014, 43:193-210.
152. Pevzner Y., Frugier E., Schalk V., Caflisch A., Woodcock H.L. Fragment-based docking: development of the CHARMMing web user interface as a platform for computer-aided drug design. J. Chem. Inf. Model. 2014, 54:2612-2620.
153. Phatak S.S., Stephan C.C., Cavasotto C.N. High-throughput and in silico screenings in drug discovery. Expert Opin. Drug Discov. 2009, 4:947-959.
154. Pihan E., Colliandre L., Guichou J.F., Douguet D. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics 2012, 28:1540-1541.
155. Pitt W.R., Montalvao R.W., Blundell T.L. Polyphony: superposition independent methods for ensemble-based drug discovery. BMC Bioinform. 2014, 15:324.
156. Polishchuk P.G., Madzhidov T.I., Varnek A. Estimation of the size of drug-like chemical space based on GDB-17 data. J. Comput. Aided Mol. Des. 2013, 27:675-679.
157. Pomowski A., Ustok F.I., Huntington J.A. Homology model of human prothrombinase based on the crystal structure of pseutarin C. Biol. Chem. 2014, 395:1233-1241.
158. Rajamani D., Thiel S., Vajda S., Camacho C.J. Anchor residues in protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11287-11292.
159. Rester U. From virtuality to reality - virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr. Opin. Drug Discov. Dev. 2008, 11:559-568.
160. Reymond J.L. The chemical space project. Acc. Chem. Res. 2015, (in press).
161. Reynes C., Host H., Camproux A.C., Laconde G., Leroux F., Mazars A., Deprez B., Fahraeus R., Villoutreix B.O., Sperandio O. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput. Biol. 2010, 6:e1000695.
162. Ripphausen P., Stumpfe D., Bajorath J. Analysis of structure-based virtual screening studies and characterization of identified active compounds. Future Med. Chem. 2012, 4:603-613.
163. Ritchie T.J., Macdonald S.J. The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design?. Drug Discov. Today 2009, 14:1011-1020.
164. Rognan D. Rational design of protein-protein interaction inhibitors. MedChemComm 2015, 6:51-60.
165. Ruddigkeit L., van Deursen R., Blum L.C., Reymond J.L. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J. Chem. Inf. Model. 2012, 52:2864-2875.
166. Rueda M., Bottegoni G., Abagyan R. Recipes for the selection of experimental protein conformations for virtual screening. J. Chem. Inf. Model. 2010, 50:186-193.
167. Ruppert J., Welch W., Jain A.N. Automatic identification and representation of protein binding sites for molecular docking. Protein Sci. 1997, 6:524-533.
168. Schmidtke P., Bidon-Chanal A., Luque F.J., Barril X. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 2011, 27:3276-3285.
169. Schneider G. Virtual screening: an endless staircase?. Nat. Rev. Drug Discov. 2010, 9:273-276.
170. Schon A., Lam S.Y., Freire E. Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions. Future Med. Chem. 2011, 3:1129-1137.
171. Schorpp K., Rothenaigner I., Salmina E., Reinshagen J., Low T., Brenke J.K., Gopalakrishnan J., Tetko I.V., Gul S., Hadian K. Identification of small-molecule frequent hitters from AlphaScreen high-throughput screens. J. Biomol. Screen. 2014, 19:715-726.
172. Scior T., Bender A., Tresadern G., Medina-Franco J.L., Martinez-Mayorga K., Langer T., Cuanalo-Contreras K., Agrafiotis D.K. Recognizing pitfalls in virtual screening: a critical review. J. Chem. Inf. Model. 2012, 52:867-881.
173. Sheridan R.P., Maiorov V.N., Holloway M.K., Cornell W.D., Gao Y.D. Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the protein data bank. J. Chem. Inf. Model. 2010, 50:2029-2040.
174. Shoichet B.K. Virtual screening of chemical libraries. Nature 2004, 432:862-865.
175. Skolnick J., Zhou H., Gao M. Are predicted protein structures of any value for binding site prediction and virtual ligand screening?. Curr. Opin. Struct. Biol. 2013, 23:191-197.
176. Smith M.C., Gestwicki J.E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 2012, 14:e16.
177. Sotriffer C.A. Accounting for induced-fit effects in docking: what is possible and what is not?. Curr. Top. Med. Chem. 2011, 11:179-191.
178. Sperandio O., Mouawad L., Pinto E., Villoutreix B.O., Perahia D., Miteva M.A. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Eur. Biophys. J. 2010, 39:1365-1372.
179. Sperandio O., Reynes C.H., Camproux A.C., Villoutreix B.O. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today 2010, 15:220-229.
180. Sperandio O., Wildhagen K.C., Schrijver R., Wielders S., Villoutreix B.O., Nicolaes G.A. Identification of novel small molecule inhibitors of activated protein C. Thromb. Res. 2014, 133:1105-1114.
181. Starzec A., Miteva M.A., Ladam P., Villoutreix B.O., Perret G.Y. Discovery of novel inhibitors of vascular endothelial growth factor-A-neuropilin-1 interaction by structure-based virtual screening. Bioorg. Med. Chem. 2014, 22:4042-4048.
182. Stumpfe D., Ripphausen P., Bajorath J. Virtual compound screening in drug discovery. Future Med. Chem. 2012, 4:593-602.
183. Sudha G., Nussinov R., Srinivasan N. An overview of recent advances in structural bioinformatics of protein-protein interactions and a guide to their principles. Prog. Biophys. Mol. Biol. 2014, 116:141-150.
184. Sun C., Petros A.M., Hajduk P.J. Fragment-based lead discovery: challenges and opportunities. J. Comput. Aided Mol. Des. 2011, 25:607-610.
185. Surade S., Blundell T.L. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 2012, 19:42-50.
186. Szilagyi A., Nussinov R., Csermely P. Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks. Curr. Top. Med. Chem. 2013, 13:64-77.
187. Taboureau O., Baell J.B., Fernandez-Recio J., Villoutreix B.O. Established and emerging trends in computational drug discovery in the structural genomics era. Chem. Biol. 2012, 19:29-41.
188. Thangudu R.R., Bryant S.H., Panchenko A.R., Madej T. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J. Mol. Biol. 2012, 415:443-453.
189. Thanos C.D., DeLano W.L., Wells J.A. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15422-15427.
190. Thevenet P., Rey J., Moroy G., Tuffery P. De novo peptide structure prediction: an overview. Methods Mol. Biol. 2015, 1268:1-13.
191. Totrov M., Abagyan R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr. Opin. Struct. Biol. 2008, 18:178-184.
192. Trosset J.Y., Vodovar N. Structure-based target druggability assessment. Methods Mol. Biol. 2013, 986:141-164.
193. Ulucan O., Eyrisch S., Helms V. Druggability of dynamic protein-protein interfaces. Curr. Pharm. Des. 2012, 18:4599-4606.
194. van Westen G.J., Gaulton A., Overington J.P. Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput. Biol. 2014, 10:e1003559.
195. Varin T., Didiot M.C., Parker C.N., Schuffenhauer A. Latent hit series hidden in high-throughput screening data. J. Med. Chem. 2012, 55:1161-1170.
196. Verbrugghe M., Verhaeghe S., Lauwaert K., Beeckman D., Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat. Rev. 2013, 39:610-621.
197. Villoutreix B.O., Bastard K., Sperandio O., Fahraeus R., Poyet J.L., Calvo F., Deprez B., Miteva M.A. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr. Pharm. Biotechnol. 2008, 9:103-122.
198. Villoutreix B.O., Kuenemann M.A., Poyet J.L., Bruzzoni-Giovanelli H., Labbe C., Lagorce D., Sperandio O., Miteva M.A. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol. Inf. 2014, 33:414-437.
199. Villoutreix B.O., Labbe C.M., Lagorce D., Laconde G., Sperandio O. A leap into the chemical space of protein-protein interaction inhibitors. Curr. Pharm. Des. 2012, 18:4648-4667.
200. Villoutreix B.O., Laconde G., Lagorce D., Martineau P., Miteva M.A., Dariavach P. Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening. PLoS One 2011, 6:e21117.
201. Villoutreix B.O., Lagorce D., Labbe C.M., Sperandio O., Miteva M.A. One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov. Today 2013, 18:1081-1089.
202. Villoutreix B.O., Renault N., Lagorce D., Sperandio O., Montes M., Miteva M.A. Free resources to assist structure-based virtual ligand screening experiments. Curr. Protein Pept. Sci. 2007, 8:381-411.
203. Villoutreix B.O., Sperandio O. In silico studies of blood coagulation proteins: from mosaic proteases to nonenzymatic cofactor inhibitors. Curr. Opin. Struct. Biol. 2010, 20:168-179.
204. Voet A., Banwell E.F., Sahu K.K., Heddle J.G., Zhang K.Y. Protein interface pharmacophore mapping tools for small molecule protein: protein interaction inhibitor discovery. Curr. Top. Med. Chem. 2013, 13:989-1001.
205. Wang Q., Zheng M., Huang Z., Liu X., Zhou H., Chen Y., Shi T., Zhang J. Toward understanding the molecular basis for chemical allosteric modulator design. J. Mol. Graph. Model. 2012, 38:324-333.
206. Wang R., Fang X., Lu Y., Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J. Med. Chem. 2004, 47:2977-2980.
207. Wanner J., Fry D.C., Peng Z., Roberts J. Druggability assessment of protein-protein interfaces. Future Med. Chem. 2011, 3:2021-2038.
208. Ward S.E., Beswick P. What does the aromatic ring number mean for drug design?. Expert Opin. Drug Discov. 2014, 9:995-1003.
209. Watkins A.M., Arora P.S. Structure-based inhibition of protein-protein interactions. Eur. J. Med. Chem. 2015, (in press).
210. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
211. Whitty A. Growing PAINS in academic drug discovery. Future Med. Chem. 2011, 3:797-801.
212. Wilson A.J. Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 2009, 38:3289-3300.
213. Winter A., Higueruelo A.P., Marsh M., Sigurdardottir A., Pitt W.R., Blundell T.L. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 2012, 45:383-426.
214. Wirth M., Volkamer A., Zoete V., Rippmann F., Michielin O., Rarey M., Sauer W.H. Protein pocket and ligand shape comparison and its application in virtual screening. J. Comput. Aided Mol. Des. 2013, 27:511-524.
215. Wlodarski T., Zagrovic B. Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19346-19351.
216. Xie Z.R., Hwang M.J. Methods for predicting protein-ligand binding sites. Methods Mol. Biol. 2015, 1215:383-398.
217. Yang C.-Y., Nikolovska-Coleska Z., Li P., Roller P., Wang S. Solution conformations of wild-type and mutated Bak BH3 peptides via dynamical conformational sampling and implication to their binding to antiapoptotic Bcl-2 proteins. J. Phys. Chem. B 2004, 108:1467-1477.
218. Zarzycka B., Seijkens T., Nabuurs S.B., Ritschel T., Grommes J., Soehnlein O., Schrijver R., van Tiel C.M., Hackeng T.M., Weber C., Giehler F., Kieser A., Lutgens E., Vriend G., Nicolaes G.A. Discovery of small molecule CD40-TRAF6 inhibitors. J. Chem. Inf. Model. 2015, 55:294-307.
219. Zerbe B.S., Hall D.R., Vajda S., Whitty A., Kozakov D. Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. J. Chem. Inf. Model. 2012, 52:2236-2244.
220. Zhang Z., Li Y., Lin B., Schroeder M., Huang B. Identification of cavities on protein surface using multiple computational approaches for drug binding site prediction. Bioinformatics 2011, 27:2083-2088.
221. Zhang X., Betzi S., Morelli X., Roche P. Focused chemical libraries - design and enrichment: an example of protein-protein interaction chemical space. Future Med. Chem. 2014, 6:1291-1307.
222. Zhang Z., Martiny V., Lagorce D., Ikeguchi Y., Alexov E., Miteva M.A. Rational design of small-molecule stabilizers of spermine synthase dimer by virtual screening and free energy-based approach. PLoS One 2014, 9:e110884.
223. Zhao H. Lead optimization in the nondrug-like space. Drug Discov. Today 2011, 16:158-163.
224. Zheng X., Gan L., Wang E., Wang J. Pocket-based drug design: exploring pocket space. AAPS J. 2012, 15:228-241.
225. Zhu T., Cao S., Su P.C., Patel R., Shah D., Chokshi H.B., Szukala R., Johnson M.E., Hevener K.E. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem. 2013, 56:6560-6572.